Home LiteratureArticle Details
PMID: 1878893 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Prospective assessment of the role of five tumour markers in breast cancer.

Cancer immunology, immunotherapy : CII ·Vol. 33 ·No. 6 ·1991-00-00 ·Pages 403-10

Robertson JF, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, Howell A

Abstract

Retrospective analysis previously identified significant elevation of five tumour markers, carcinoembryonic antigen (CEA), ferritin, orosomucoid. C-reactive protein and erythrocyte sedimentation rate (ESR), in patients with systemic breast cancer and showed that changes in each of these markers individually correlated significantly with therapeutic response. In this study we have prospectively tested these findings. None of the five markers was significantly elevated in primary breast cancer compared to normal control or benign breast disease groups. They therefore appear to have no role either in screening or in the differential diagnosis of breast cancer. There was a significant elevation of all five markers in patients with systemic breast cancer (P less than 0.0001: analysis of variance) but sequential changes in CEA and ESR only correlated significantly with the UICC-assessed response. Prospective confirmation of the correlation between changes in serum CEA and ESR provides the basis for using these markers in the assessment of response to therapy in patients with systemic breast cancer.

MeSH Terms
Adult Aged Biomarkers, Tumor/blood Blood Sedimentation Breast Neoplasms/blood,therapy C-Reactive Protein/analysis Carcinoembryonic Antigen/blood Female Ferritins/blood Humans Middle Aged Neoplasm Metastasis Orosomucoid/analysis Prospective Studies
Chemicals
Biomarkers, Tumor Carcinoembryonic Antigen Orosomucoid C-Reactive Protein Ferritins
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Robertson J F
Unit of Surgery, City Hospital, Nottingham, UK.
Pearson D
Price M R
Selby C
Pearson J
Blamey R W
Howell A
References (42)
42 references, click to expand
  1. Serum sialic acid and CEA concentrations in human breast cancer.
    Br J Cancer. 1980 Apr;41(4):587-92 PMID: 7387856
  2. Biochemical markers in human breast cancer.
    Lancet. 1977 Jan 15;1(8003):132-4 PMID: 64663
  3. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio. Comparisons with carcinoembryonic antigen and human chorionic gonadotrophin.
    Cancer. 1978 May;41(5):1871-82 PMID: 647632
  4. Carcinoembryonic antigen in serum of unselected breast-cancer patients and of non-hospitalized controls.
    Br J Cancer. 1979 Feb;39(2):109-15 PMID: 435362
  5. Carcinoembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy.
    Cancer. 1978 Sep;42(3):1308-13 PMID: 698917
  6. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: a predictor and monitor of response and relapse.
    Ann Intern Med. 1978 Dec;89(6):902-6 PMID: 717986
  7. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases.
    Scand J Immunol. 1984 Mar;19(3):193-8 PMID: 6200925
  8. Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer.
    Eur J Cancer. 1975 Sep;11(9):615-8 PMID: 1220977
  9. Prognostic significance of CEA in breast cancer: a statistical study.
    Eur J Cancer Clin Oncol. 1981 Dec;17(12):1307-13 PMID: 7200032
  10. Is the carcinoembryonic antigen test a valid predictor of response to medical therapy in disseminated breast cancer?
    Tumori. 1986 Oct 31;72(5):515-8 PMID: 3798573
  11. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents.
    Arch Biochem Biophys. 1974 Jun;162(2):493-501 PMID: 4210077
  12. Screening for metastases in breast cancer: an assessment of biochemical and physical methods.
    Cancer. 1981 Jul 15;48(2):310-5 PMID: 6113047
  13. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review.
    Eur J Surg Oncol. 1988 Oct;14(5):417-22 PMID: 3181446
  14. Evaluation of carcinoembryonic antigen in human mammary carcinoma.
    J Natl Cancer Inst. 1973 Oct;51(4):1119-22 PMID: 4745852
  15. Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer.
    Ir J Med Sci. 1980 Dec;149(12):469-74 PMID: 7228593
  16. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress.
    Cancer. 1974 May;33(5):1246-52 PMID: 4823478
  17. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.
    Br J Cancer. 1990 Jan;61(1):126-32 PMID: 2137007
  18. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma.
    Cancer. 1978 Sep;42(3 Suppl):1512-9 PMID: 709523
  19. A biochemical approach to the staging of human breast cancer.
    Cancer. 1977 Aug;40(2):937-44 PMID: 890676
  20. Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen.
    Cancer. 1977 Jun;39(6):2397-404 PMID: 872038
  21. Biologic markers and breast cancer: a multiparametric study--1. Increased serum protein levels.
    Cancer. 1982 Feb 1;49(3):502-12 PMID: 6977405
  22. Serial tests of carcinoembryonic antigen in patients with breast cancer.
    Am J Clin Oncol. 1983 Jun;6(3):287-93 PMID: 6846246
  23. Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer.
    Eur J Cancer Clin Oncol. 1984 Jan;20(1):25-31 PMID: 6537913
  24. Metastatic breast cancer with constantly low CEA blood levels. A subgroup with unfavorable prognosis?
    J Cancer Res Clin Oncol. 1984;108(3):341-4 PMID: 6511807
  25. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.
    Eur J Cancer Clin Oncol. 1989 Mar;25(3):469-75 PMID: 2703001
  26. Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma.
    Br Med J. 1972 Sep 9;3(5827):605-9 PMID: 5071695
  27. Tumour markers in breast cancer.
    Br J Cancer. 1979 Nov;40(5):710-8 PMID: 92331
  28. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer.
    Eur J Surg Oncol. 1990 Feb;16(1):22-7 PMID: 2137790
  29. Serum alpha-1-acid glycoprotein as an index of dissemination in breast cancer.
    Br J Surg. 1975 Oct;62(10):816-9 PMID: 1191942
  30. Carcinoembryonic antigen and other tumor markers in tissue and serum or plasma of patients with primary mammary carcinoma.
    Cancer. 1978 Oct;42(4):1870-8 PMID: 361213
  31. Multivariate biochemical indicators of breast cancer: an evaluation of their potential in routine practice.
    Eur J Cancer. 1978 Aug;14(8):885-93 PMID: 80319
  32. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
    Cancer Detect Prev. 1985;8(1-2):35-45 PMID: 4064050
  33. Clinical correlation between CEA and breast cancer.
    Cancer. 1978 Sep;42(3 Suppl):1507-11 PMID: 709522
  34. Human tissue polypeptide antigen in breast cancer.
    J Natl Cancer Inst. 1979 Dec;63(6):1347-50 PMID: 292806
  35. Carcinoembryonic antigen: its role as a marker in the management of cancer. Summary of an NIH consensus statement.
    Br Med J (Clin Res Ed). 1981 Jan 31;282(6261):373-5 PMID: 6780032
  36. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.
    Cancer. 1977 Mar;39(3):1289-94 PMID: 912660
  37. Carcinoembryonic antigen (CEA): its role as a tumour marker in breast cancer.
    Clin Oncol. 1981 Mar;7(1):53-8 PMID: 7214765
  38. Assessment of response to treatment in advanced breast cancer. British Breast Group.
    Lancet. 1974 Jul 6;2(7871):38-9 PMID: 4134716
  39. Significance of serum concentrations of carcinoembryonic antigen, ferritin, and calcitonin in breast cancer.
    Cancer. 1981 Oct 1;48(7):1623-8 PMID: 7284963
  40. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy.
    Cancer. 1984 Feb 1;53(3):577-82 PMID: 6692261
  41. [Diagnostic validity of CEA determination in metastasizing breast cancer].
    Klin Wochenschr. 1986 Aug 1;64(15):701-7 PMID: 3762017
  42. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.
    Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567-72 PMID: 3208800
Article Info
Journal
Cancer immunology, immunotherapy : CII
Abbr.
Cancer Immunol Immunother
ISSN
0340-7004
DOI
10.1007/BF01741602
Published
1991-00-00
Pages
403-10
Language
English
Region
Germany
NLM ID
8605732
Subset
IM
External Links
PubMed source DOI: 10.1007/BF01741602 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2